The grants came through the National Institute of Allergy and Infectious Diseases and the National Science Foundation.
Join us on Thursday, January 11 for the 2017-18 Spring Term FAES Graduate School Open House to meet and mingle with FAES faculty. Bring yourself, a friend, and your questions about registering for the Spring 2018 courses. The event will be held in the FAES Academic Center, Building 10, NIH, Bethesda, MD, 4:00 – 6:00 PM. Light refreshments will be served!
The biopharma sector has had quite a year. Under FDA Commissioner Scott Gottlieb, the regulator approved a record number of drugs and helped usher in innovative gene therapy treatments. Behavioral health drugs also marked a milestone with the approval of Otsuka Pharmaceutical’s Abilify MyCite, embedded with a sensor developed by Proteus Digital Health to remotely monitor medication adherence for people with schizophrenia and bipolar disorders.
The FDA has released a range of decisions regarding the agency’s role in regulating digital health technologies since Scott Gottlieb, MD, assumed the role of commissioner in May.
Here are three highlights from the FDA’s year in digital health.
In covering the D.C. innovation economy comes the inevitable: funding news. Trust us, there’s a lot of it floating around the D.C. metro area. Here’s a roundup of all of the major funding news from the region in December:
Dr. David Feinberg has served as president and CEO of Danville, Pennsylvania-based Geisinger since 2015. Previously, he was president of UCLA Health System, CEO of UCLA’s hospitals and associate vice chancellor of UCLA Health Sciences.
New Enterprise Associates made the most venture deals for the second year in a row in 2017, with 125 investments totaling $914 million, according to VCJ’s analysis of preliminary Thomson Reuters data through mid-December.
Precision Medicine Group announced it had raised $275 million. The round was led by Berkshire Partners and TPG Growth, with participation from its co-founders and management team, as well as original investors Oak Investment Partners and J.H. Whitney.
When the University System of Maryland set its strategic plan for the next 10 years in 2010, it hoped to double the system’s externally sponsored research and development funding from $1.2 billion to $2.4 billion. Instead, as federal dollars have dried up, that number has remained relatively flat, up to just $1.27 billion with three years
Global pharmaceutical company Mallinckrodt Plc (NYSE: MNK) has entered an agreement to buy Rockville’s Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) for $1.2 billion including debt.